Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Coronary Arteriosclerosis: full-pipeline trial registry
A small indexed set (12 trials) with no open enrollment listed right now.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · none currently recruiting · #1,429 of 28,707 conditions by registered trial count
Coronary Arteriosclerosis: 12 US clinical trials tracked, none currently recruiting.
Coronary Arteriosclerosis is the subject of 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 2 of these trials.
Enrollment posture brief
Registry condition coronary-arteriosclerosis
OPEN 0 | RECR 0% | LATE 2 | EARLY 3 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of the Gastroesophageal Junction (0% recruiting · 8 trials)
Coronary Arteriosclerosis has no open enrollment in this registry pull (12 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Coronary Arteriosclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Coronary Arteriosclerosis is recruiting below its size-band peers.
0 of 12 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Coronary Arteriosclerosis research.
Pfizer accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Coronary Arteriosclerosis enrolment sits around 550 participants.
Median target enrolment is 550 among the 12 trials that report a genuine target (sentinel values excluded). 1 of those (8.3%) plan for fewer than 100 participants.
-
Coronary Arteriosclerosis research is mostly interventional.
12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique
Massachusetts General Hospital
NCT00540761
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
Accumetrics
NCT00645918
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
Pfizer
NCT00134173
Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)
Stanford University
NCT00267774
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
Pfizer
NCT00380939
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
OrbusNeich
NCT02073565
Multidisciplinary Inpatient Palliative Care Intervention
Kaiser Permanente
NCT00325611
Estrogen, HDL, and Coronary Heart Disease in Women
Tufts University
NCT00083824
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
Avant Immunotherapeutics
NCT00082121
Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)
Johns Hopkins University
NCT00353795
Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients
Providence VA Medical Center
NCT00357955
Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT00069654
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Coronary Arteriosclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Coronary Arteriosclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Coronary Arteriosclerosis page
12 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Coronary Arteriosclerosis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Pfizer sponsors the most Coronary Arteriosclerosis trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Arteriosclerosis condition card totals 12 registered trials; most-linked intervention Estrogens, Conjugated (USP); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.